顶部联系方式

Time of issue:2019-09-22 00:00:00
EN
SEARCH
Confirm
Cancel

HUAPONT PHARM

NEWS

Bexarotene - Potential COVID-19 treatments with recent research
Check category

Bexarotene - Potential COVID-19 treatments with recent research

  • Categories:2020
  • Author:
  • Origin:
  • Time of issue:2020-06-29 10:20
  • Views:0

【Summary】Since the outbreak of the Coronavirus Disease 2019(COVID-19), many parties around the world are looking for the effective drugs to treat the disease. The latest research found that Bexarotene showed significant efficacy in the COVID-19 treatment.

A few clinically approved drugs, such as remdesivir, chloroquine, hydroxychloroquine, nafamostat, camostat, and ivermectin, exhibited anti-SARS-CoV-2 activity in vitro and/or in a small number of patients. However, their clinical use may be limited by anti-SARS-CoV-2 50 % maximal effective concentrations (EC50) that exceeded their achievable peak serum concentrations (Cmax), side effects, and/or availability. To find more immediately available COVID-19 antivirals. The Author established a two-tier drug screening system that combines SARS-CoV-2 enzyme-linked immunosorbent assay and cell viability assay, and applied it to screen a library consisting 1528 FDA-approved drugs. Cetilistat (anti-pancreatic lipase), diiodohydroxyquinoline (anti-parasitic), abirateroneacetate (synthetic androstane steroid), and bexarotene (antineoplastic retinoid) exhibited potent in vitro anti-SARS-CoV-2 activity (EC501.13–2.01μM). Bexarotene demonstrated the highest Cmax: EC50 ratio (1.69) which was higher than those of chloroquine, hydroxychloroquine.

Article:Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system

Bexarotene - Potential COVID-19 treatments with recent research

【Summary】Since the outbreak of the Coronavirus Disease 2019(COVID-19), many parties around the world are looking for the effective drugs to treat the disease. The latest research found that Bexarotene showed significant efficacy in the COVID-19 treatment.

A few clinically approved drugs, such as remdesivir, chloroquine, hydroxychloroquine, nafamostat, camostat, and ivermectin, exhibited anti-SARS-CoV-2 activity in vitro and/or in a small number of patients. However, their clinical use may be limited by anti-SARS-CoV-2 50 % maximal effective concentrations (EC50) that exceeded their achievable peak serum concentrations (Cmax), side effects, and/or availability. To find more immediately available COVID-19 antivirals. The Author established a two-tier drug screening system that combines SARS-CoV-2 enzyme-linked immunosorbent assay and cell viability assay, and applied it to screen a library consisting 1528 FDA-approved drugs. Cetilistat (anti-pancreatic lipase), diiodohydroxyquinoline (anti-parasitic), abirateroneacetate (synthetic androstane steroid), and bexarotene (antineoplastic retinoid) exhibited potent in vitro anti-SARS-CoV-2 activity (EC501.13–2.01μM). Bexarotene demonstrated the highest Cmax: EC50 ratio (1.69) which was higher than those of chloroquine, hydroxychloroquine.

Article:Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system

  • Categories:2020
  • Author:
  • Origin:
  • Time of issue:2020-06-29 10:20
  • Views:0
Information

Since the outbreak of the Coronavirus Disease 2019(COVID-19), many parties around the world are looking for the effective drugs to treat the disease. The latest research found that Bexarotene showed significant efficacy in the COVID-19 treatment.

A few clinically approved drugs, such as remdesivir, chloroquine, hydroxychloroquine, nafamostat, camostat, and ivermectin, exhibited anti-SARS-CoV-2 activity in vitro and/or in a small number of patients. However, their clinical use may be limited by anti-SARS-CoV-2 50 % maximal effective concentrations (EC50) that exceeded their achievable peak serum concentrations (Cmax), side effects, and/or availability. To find more immediately available COVID-19 antivirals. The Author established a two-tier drug screening system that combines SARS-CoV-2 enzyme-linked immunosorbent assay and cell viability assay, and applied it to screen a library consisting 1528 FDA-approved drugs. Cetilistat (anti-pancreatic lipase), diiodohydroxyquinoline (anti-parasitic), abirateroneacetate (synthetic androstane steroid), and bexarotene (antineoplastic retinoid) exhibited potent in vitro anti-SARS-CoV-2 activity (EC501.13–2.01μM). Bexarotene demonstrated the highest Cmax: EC50 ratio (1.69) which was higher than those of chloroquine, hydroxychloroquine.

Article:Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system

Scan the QR code to read on your phone

  • Bexarotene-COVID 19.pdf

    Size:
    2020-06-28 18:02:02
Bangbang Bird

QUICK LINKS

Quick Links

Time of issue:2020-05-28 00:00:00

CONTACT INFO

Contact Info

Time of issue:2020-05-28 00:00:00

TEL: +86-23-67886927

TEL: +86-23-67886928

EMAIL: api@huapont.cn

ADD.: No.69 Xingguang Avenue, Renhe Town, Yubei District,Chongqing, China 401121

FEEDBACK

留言应用名称:
feedback
Description:
验证码

地址版权

Time of issue:2019-09-22 00:00:00

© 2020 Chongqing Huapont Pharmaceutical Co., Ltd. All Rights Reserved. Powered by: www.300.cn 渝ICP备05003324号

手机版地址版权

Time of issue:2019-09-22 00:00:00

© 2020 Chongqing Huapont Pharmaceutical Co., Ltd.

Powered by: www.300.cn 渝ICP备05003324号